Market research
IPCALAB.NSE Ipca Laboratories Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 485B
- P/E ratio
- 36.98
- Analyst target
- 1972.2778
- Dividend yield
- 0.0%
- Beta
- 0.04
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE571A01038
- Market cap
- 485B
- P/E ratio
- 36.98
- Analyst target
- 1972.2778
- Dividend yield
- 0.0%
- Beta
- 0.04
About
About Ipca Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IPCALAB.NSE discussion.
5 years, 4 months ago
Ipca Laboratories Limited is currently in a long term uptrend where the price is trading 1.6% above its 200 day moving average.
From a valuation standpoint, the stock is 6.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Ipca Laboratories Limited's total revenue rose by 16.2% to $14B since the same quarter in the previous year.
Its net income has increased by 34.3% to $3B since the same quarter in the previous year.
Finally, its free cash flow fell by 0.0% to $4B since the same quarter in the previous year.
Based on the above factors, Ipca Laboratories Limited gets an overall score of 4/5.